Brookline Capital Management Estimates OTLK FY2025 Earnings

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Analysts at Brookline Capital Management dropped their FY2025 earnings per share estimates for shares of Outlook Therapeutics in a research note issued to investors on Wednesday, November 27th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($1.80) for the year, down from their prior forecast of ($1.64). The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics’ Q4 2025 earnings at ($0.36) EPS, FY2026 earnings at $0.61 EPS and FY2027 earnings at $1.18 EPS.

Several other research firms also recently weighed in on OTLK. Chardan Capital reissued a “buy” rating and issued a $53.00 target price on shares of Outlook Therapeutics in a research report on Friday, August 16th. Ascendiant Capital Markets cut their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a report on Friday. Finally, BTIG Research lowered their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Outlook Therapeutics presently has an average rating of “Buy” and a consensus target price of $42.34.

Outlook Therapeutics Trading Up 20.6 %

NASDAQ OTLK opened at $2.05 on Monday. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85. The company has a market cap of $48.50 million, a PE ratio of -0.19 and a beta of 0.62. The stock’s 50-day moving average price is $5.29 and its two-hundred day moving average price is $6.70.

Insider Activity

In other news, CFO Lawrence A. Kenyon purchased 5,000 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was acquired at an average price of $5.69 per share, with a total value of $28,450.00. Following the purchase, the chief financial officer now owns 5,946 shares in the company, valued at $33,832.74. This represents a 528.54 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Outlook Therapeutics

A number of institutional investors have recently added to or reduced their stakes in OTLK. Great Point Partners LLC raised its holdings in shares of Outlook Therapeutics by 15.0% during the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after purchasing an additional 221,510 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Outlook Therapeutics during the second quarter worth $303,000. Squarepoint Ops LLC bought a new position in Outlook Therapeutics during the second quarter valued at about $232,000. Christensen King & Associates Investment Services Inc. acquired a new stake in shares of Outlook Therapeutics in the third quarter worth about $55,000. Finally, AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics during the 2nd quarter worth about $75,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.